OOIR: Observatory of International Research

Papers

(The TQCC of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The Design of SPRINT MIND and SPRINT MIND 2020	2760
Survey on knowledge of Uruguayan neurologist about the FINGER intervention	1960
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory	1951
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances	751
The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis	504
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study	450
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease	407
Neural flexibility as a promising biomarker for Alzheimer’s Disease	266
The Types and Consistency of Participant‐Specified Proxies During SPRINT	232
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	224
Putative Cellular Identity of Dystrophic Neurites in FTLD‐TDP Type C	208
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	200
Investigating the Association Between P2Y12 Receptor, SV2A, and Tau Expression in Postmortem AD and Control Brains Using In Vitro Autoradiography	196
Neuroprotective Potential of Limonene in LPS induced Parkinson’s Disease in Rats	188
Glial and synaptic biomarkers as early indicators of mild cognitive decline	182
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease	165
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	153
Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change	147
Physical Activity, Social Support, and the Health of Dementia Caregivers: A Scoping Review	138
Frontotemporal Dementia & the Criminal Legal System: Care Partner Stories	136
Childhood trauma and cognition status in an elderly sample with a mental disorder	129
SENSE‐Cog Residential Care: A Pilot Cluster Randomized Trial on Hearing and Vision Support for Residents with Dementia in Long‐term Care	126
Digits Across Languages: The Role of Lexical and Numerical Characteristics in Digit Span Performance Across Fourteen Languages	115
Who Uses Memory Strategies? Exploring the Influence of Cognitive Reserve on Use of Memory Strategies by Older Adults Referred for Neuropsychological Assessment	112
Reducing Gerontophobia and Improving Cognition: A Study on the Efficacy of Mindfulness‐Based Cognitive Therapy in Older Adults in India	110

“CLOVER” Model of Service and Training Development for the Well‐being of People with Dementia in Residential Care Homes of Hong Kong	110
Ciclosonide reduces lipid droplet burden in APOE4 astrocytes	110
The Dementia Literacy Assessment (DeLA): A Novel Measure of Alzheimer's Disease and Related Disorders Health Literacy in Diverse Populations	100
An interrupted time‐series design experiment of research registry recruitment interventions	99
Pterostilbene Ameliorates Hyperhomocysteinemia‐Induced Cognitive Impairment: Involvement of Mitochondrial Dysfunction, Synaptic Plasticity, and Adult Neurogenesis	99
Herbal Therapeutics in Alzheimer's Disease: Investigating Behavioral and Biochemical Changes in Animal Model	96
“ I know you didn’t want to stay ”: Emergency Department Conversations about Disposition for People Living with Dementia	95
Dementia registry in Guinea: clinical and etiological aspects at the Neurological Department of the Conakry teaching Hospital	93
Simultaneous reduction of amyloid beta and phosphorylated tau for Alzheimer’s Disease with Chemically Optimized Stringed Modifiable Oligonucleotides (COSMOs)	93
Impact of icosapent ethyl on CSF NULISA vascular, metabolic, and AD biomarkers in cognitively unimpaired Veterans at risk for dementia	92
The Utility of the WMS‐IV LM Subtest as an Inclusionary Measure in Early AD Trials	92
Natural Language Processing differentiates between Italian individuals with Nonfluent/Agrammatic from Logopenic variants of PPA	90
Anti‐NMDA Receptor Encephalitis in a Young Adult with Neuropsychiatric and Cognitive Symptoms‐ A Case Study	90
The glymphatic system's role in linking cardiometabolic health to cerebral small vessel disease and frailty in Chilean healthy older adults	89
False Negative Twenty‐Nine Montreal Cognitive Assessment Score in Moderately ADL‐Impaired UDS Patients: A Case Series Study of 23 Patients	89
Neuropsychiatric symptom subtypes associated with Alzheimer's disease and related dementia neuropathologic changes in the National Alzheimer's Coordinating Center neuropathology cohort	85
Cross‐ validation of Free‐Cog with routinely used cognitive and functional tools in Canadian Memory Clinics	84
Neuropsychiatric Symptoms in Comorbid Alzheimer's Disease Neuropathologic Change and Frontotemporal Lobar Degeneration	84
Association of MBI‐C scores with clinical outomes in patients with MCI during a 3‐year follow‐up	83
Implementation of AD BBMs: Approach in Memory Clinics in the Netherlands	83
Genetic Intersections of ADHD and Alzheimer's Disease: A Systematic Review	82
Effect of Orexin receptor antagonists for patients with Lewy bodies: Lemborexant do not make worse cognitive function and REM sleep Behavior Disorder in DLB	81
Achieving Dissemination and Implementation Success in Dementia Care: A Consideration of Methodological Strategies	80
The Impact of Testing Environments on Remote Cognitive Assessments in Alzheimer's Disease	79
Trip‐Based Measures of Naturalistic Driving: Exploring connections to older adult drivers with respect to amyloid‐positive and amyloid‐negative	78
Predicting brain health in older adults through automated language measures	77
Low‐Dose Interleukin‐2 in Patients with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial	77
Sensory Healthcare for People with Dementia in Diverse Care Settings	76
Women are less likely to be eligible for AD trials than men.	76
Rare Dementia Support Canada: Localizing and mobilizing knowledge to build inclusive supports for families affected by atypical dementias	75
Nutritional status and eating disturbances among patients with neurocognitive disorder	74
Distinct trajectories of subjective cognitive decline before diagnosis of neurocognitive disorders: Longitudinal modelling over 18 years	74
Evaluating the effect of ethnicity and amyloid on gait speed in the Healthy Aging Brain Study‐Health Disparities Study	73
Cerebellar degeneration and its integrative role in brain networks for social cognition in early‐stage bvFTD	73
The Moderating Effect of Perceived Susceptibility and Decision Conflict on the Relationship Between Comorbidities and Quality of Life Among Caregivers of People with Dementia	73
EMA perspective on Diagnosis of Alzheimer's	73
Pulse pressure is associated with Alzheimer's disease pathology and cognitive decline	72
Evaluating the impact of delayed auditory feedback in primary progressive apraxia of speech: acoustic, perceptual, and patient reported outcomes	71
Dementia Dastan: Understanding the Experiences of South Asian Canadians Living with Dementia and their Care Partners	71
Domestic Environment of Multisensory Stimulation based on Snoezelen principles pilot study	71
What is the prevalence of impaired cognitive domains in surgical patients? A systematic review and meta‐analysis	70
Divergent Functional Capacity in Alzheimer's Disease and Frontotemporal Dementia: Insights from the Peruvian Adaptation of the Amsterdam Instrumental Activities of Daily Living Questionnaire	69
The Psychological Impact of Receiving a Biomarker Informed ADRD Diagnosis in a Real‐World Sample: the PARADE Study	68
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk	67
Exploring Emotional Well‐Being in Exceptional Aging: Data from the SuperAging Research Initiative	67
Exploring Memory Trajectories in Aging: A Longitudinal Study of Superagers and Memory Maintenance	66
Speed of cognitive decline in biomarker stratified SCD subgroups	66
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy	66
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	65
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	65

Automating the verbal paired associates test to assess memory remotely and at scale	65
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	65
Regional correlation analysis between neuronal metabolism and synaptic density using [18F]FDG and [11C]UCB‐J	65
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	64
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	63
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	63
Neuropathology of a patient with AD treated with low doses of verubecestat	63
Short antibiotic treatment followed by regular administration of acid suppressant (proton pump inhibitor) reduce AB42 load in the brain and in the gut.	63
TREM2 Burden associates solely with Alzheimer’s Disease, and decreases the Chance to become a Centenarian	62
Whole‐exome sequencing of a Portuguese cohort of early‐onset Alzheimer’s disease implicates X‐linked lysosomal gene GLA	61
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	60
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	60
Human postmortem studies as a driver of biomarker development	60
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	58
Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly	58
Widespread transposable element dysregulation in human brains with Alzheimer’s disease	58
Addressing the gaps of the functional neuroimaging in young APOEe4 carriers: A systematic review and Graph Theoretical analysis of brain connectivity	57
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	57
Cerebral Small Vessel Disease and Gait Speed in Older Adults without Dementia	57
Automated word class and person usage metrics as markers of Alzheimer’s and frontotemporal dementia	56
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	56
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	55
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	55
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	55
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	54
Anti‐ulcer drug teprenone clinical trial	54
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	54
Synthetic FDG‐PET hypometabolism sensitivity validation in AD	53
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	53
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiences	53
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	52
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	52
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	51
Combined effect of prebiotic and probiotic strains restores cognitive impairment via attenuating synaptosis in the hippocampus of mice fed with high fat diet and streptozotocin diabetes‐induced dement	51
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	51
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	51
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	51
A portable eye tracking experiment for the assessment of cognitive impairment in presymptomatic frontotemporal dementia	50
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	50
Observations on biomarkers in Roche Abeta‐targeting monoclonal antibody trials	50
A retinal tauopathy with a characteristic molecular pattern points to the existence of a “Primary retinal tauopathy”	49
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	49
Automated lexical analysis of story recall in healthy controls	49
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	47
Elderly Role Performance Occupational Therapy	47
The App^NL‐G‐F/MAPT mouse model of Alzheimer’s Disease demonstrates increased levels of ptau217 in CSF, changes that correlate with increased cerebral p‐tau depositions	47
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	47
Perceptions of Shared decision making in cognitive impairment of LTC recipients	47
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	46
Impact of the COVID‐19 Pandemic on Patients with Dementia or Parkinson’s Disease and their Caregivers in Lima, Peru	46
Longitudinal patterns of behavioral and psychological symptoms of dementia in community‐dwelling older people	46
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	46
Exploring Narrative Identity via Linguistic Positioning in the Context of Alzheimer’s Dementia Risk Prediction – an Ethical and Linguistic Analysis	46
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	46
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	46
Identification of objective cognitive decline in preclinical Alzheimer’ disease	45
Preliminary Evidence for the Combined Efficacy of Focused Ultrasound Blood‐Brain Barrier Opening and Delivery of a Novel Anti‐Amyloid Re Complex for Memory Improvement in a 3xTg‐Alzheimer’s Disease Mo	45
Clinical outcome assessments for LBD trials – Should we borrow?	45
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	45
Issue Information	45
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	45
Microglial‐targeted nSMase2 inhibitor fails to reduce tau spread in the animal model of Alzheimer’s disease	45
Delivery of incretin receptor agonists to the brain	44
The association between air pollution and dementia: results from the Cognitive Function and Ageing Study II and Wales	44
Impact of Mid‐ and Late‐Life Diabetes in the Trajectories of Cognitive Aging in a Bi‐ethnic Cohort of Mexican Americans and Non‐Hispanic White Older Adults	44
Impact of Site Size on Data Quality in Early Alzheimer’s Disease Clinical Trials	44
Comparative efficacy of cholinesterase inhibitors and memantine on cognition in AD patients with application of network meta‐analysis	44
CD33 competitive inhibitor peptide IMAD‐001 modulates innate immunity in Alzheimer’s disease	44
Development of pyroptosis inhibitors for Alzheimer’s disease	44
Analytical Choices of Timescale in the Presence of Practice and Cohort Effects in Longitudinal Cognitive Aging Research: A Simulation Study Using Linear Mixed‐Effects Models	43
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	43
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	43
Prevalence of risk factors for dementia and association with cognitive alterations in an elderly population from the South of Brazil	42
Sex modifies the associations of regional fat with cognitive functioning and AD‐related brain volumes, in Israeli middle‐aged adults at high AD risk	42
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	42
	42
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	42
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	42
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	41
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	41

Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	41
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	41
A Comparison of the Prevalence of Diabetes between Aging Rural and Urban Indians.	41
Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case‐control study using Dutch primary care data	41
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	41
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	41
Relation Between Educational Attainment and Cerebral Small Vessel Disease: the Framingham Heart Study	40
Impact of Metabolic Syndrome Longitudinal Changes on Cognitive Health: A 10‐Year Follow‐up Study in Middle‐Aged Adults	40
Short‐term Sirolimus Treatment Restores Hippocampus and Caudate Volumes and Global Cerebral Blood Flow in Asymptomatic APOE4 Carriers Compared with Non‐carriers	40
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	40
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	40
Improvement of Knowledge and Research Attitudes on Preclinical Alzheimer’s Disease Trials through Community‐based Education Among Underrepresented Korean, Filipino, and Hispanic Americans	40
Social media responses to the approval of lecanemab in Japan: sentiment analysis	40
Additive Impact of Cardiometabolic Multimorbidity and Depression on Cognitive Decline: Findings from Multi‐Regional Cohorts and Generalization from Community to Clinic	40
Engaging and Recruiting Latino‐led Community Organizations to Build Workforce Capacity in AD/Brain Health Prevention Research	40
Diffusion MRI subnetwork efficiency is associated with cognitive resilience to AD pathology in cognitively unimpaired older adults at risk of AD dementia	39
The moderating effect of APOE E4 on the association of plasma biomarkers with markers of cognition and brain health in Alzheimer’s disease	39
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	39
The potential protective benefit of personality on subjective cognitive decline related worry: Results from the Canadian Longitudinal Study on Aging (CLSA)	39
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	39
Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research	38
Applying novel EMBRACE technological solutions to measure and optimize brain response to exercise.	38
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	38
Racial differences in white matter hyperintensity load in aging, MCI, and AD	38
Bibliographic Analysis of Aging Anxiety and Lifestyle	38
How well is Brazil prepared for a disease‐modifying Alzheimer’s treatment?	38
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	37
Association between plasma inflammatory biomarkers and [¹⁸F]FDG‐PET signal in a transgenic amyloid rat model	37
Syzigium aromaticum may protect against paraquat mediated toxicity via p53 and Sestrin2 modulation	37
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP	37
Associations between blood‐based biomarkers and other outcomes related to Alzheimer’s disease	37
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	37
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	37
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	37
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	37
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	36
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	36
Hub vulnerability and short path length to entorhinal cortex are associated with tau binding in Alzheimer’s disease: a combined MEG/PET study	36
Risk knowledge and risk perception of MCI patients and their caregivers in predictive diagnosis of AD: Findings from the PreDADQoL study	36
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	36
APOE loss‐of‐function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology	36
Is QEEG an effective biomarker in predicting cognitive decline?	36
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	35
The Advanced Therapeutics for Alzheimer’s Disease Review Board: A Multidisciplinary Model to Facilitate Safe Access to Lecenemab across the Sutter Health System	35
	35
APOEε4 facilitates the accumulation and connectivity‐mediated spreading of tau pathology at lower amyloid levels	35
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	35
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	35
The role of clusterin and the variant rs11136000_T throughout the spectrum of Alzheimer’s disease	35
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	35
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	35
Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective	35
Comparison of histological delineation of the entorhinal, perirhinal, ectorhinal, and parahippocampal cortices by different neuroanatomy laboratories	34
Association of the learning ratio with AD biomarkers after application of actuarial diagnostic criteria to ADNI cognitively normal participants	34
A cluster randomized trial: Exploratory quantitative analysis comparing resident outcomes for two approaches to promote non‐pharmacological, resident‐centered dementia care in nursing homes	34
A passive, neural correlate of verbal fluency in Mild Cognitive Impairment using Fastball neurocognitive assessment	33
Issue Information	33
Lithium carbonate treatment decrease neuroinflammation and ameliorates long‐term memory in a Down syndrome animal model	33
Motor alterations associated with cognitive impairment in a third‐level hospital	33
Sex and APOE differences in Alzheimer’s Disease‐On‐Ramp risk factor profiles: Are all risk factors for Alzheimer’s Disease created equal?	33
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	33
Developing a preference‐based quality of life for people living with dementia in Vietnam	33
A Machine Learning Approach to Identify Individualized Baseline MRI, Plasma, Cardiovascular and Lifestyle Predictors of a 5‐Year Cognitive Decline	33
Description of the Gut Microbiome Composition in Puerto Ricans with Alzheimer’s Disease Compared to Healthy Controls	33
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	33
Seizures exacerbate tau spread in the 5XFAD mouse model	33
Movement with Dementia: A feasibility study of a resource to support the personalisation of therapeutic exercise programmes for people living with dementia	33
Testamentary Capacity Assessment Tool (TCAT): An update report	32
Increased fibrin deposition in the brains of individuals with Down syndrome and Alzheimer’s disease	32
Persistent DNA damage response drives cGAS‐STING mediated neuroinflammation in a mouse model of tauopathy	32
Production and characterization of human tau protein with site‐specific phosphorylation utilizing E. coli with an expanded genetic code	32
Dynamic disease‐associated gene regulatory transitions unmask genetic risk associated neurodegenerative cell states	32
The role of impaired oxidative base lesion repair in Alzheimer’s disease	32
Expanded bile acid annotations linked to diet and AD biomarkers	32
Complement receptor 1 length polymorphism impacts glial functions relevant to Alzheimer’s disease	32
Proteomics identification of novel proteins dysregulated in Alzheimer’s Disease with potential as blood‐based biomarkers and related to Amyloid‐Beta Plaques	32
Interaction between polymorphisms in MBP and EIF2B5 genes is significantly associated with Alzheimer’s disease	32
Multiple pathological mechanisms of Bin1 for tau aggregation and propagation	31
Whole blood DNA methylation profiles of Alzheimer’s disease differ across ancestrally diverse populations	31
Prevalence of dementia diagnoses in a safety net health system	31
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	31
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	31
EEG microstates as a “real time” feedback for rTMS treatment efficacy in MCI subjects	31
Retinal Examination in Neurodegenerative Diseases of the Brain	31
Associations between imaging biomarkers and sleep quality in the U.S. POINTER study baseline cohort	31
Integrative Analysis of Genetic Network and Brain Imaging using Generative Models for Alzheimer’s Disease Prediction	31
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	31
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	31
Targeted Multiplexed MALDI MS Platform Enables Detection of Novel Pathogenic Forms of Tau, Amyloid Beta and Alpha Synuclein	31
Anosognosia and caregiver distress independently identify subjects at high risk of developing dementia of Alzheimer’s type	31
Methods in Prioritizing Pathways and Targets from Expression Data	30
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	30
Contrast of Early Phase Amyloid PET	30
AD‐Associated Variants Directly Impair Surface Interactions Between the Hydrophobic Site of TREM2 and the Hinge Region of ApoE	30
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	30